Claims for Patent: 8,329,179

Summary for Patent: 8,329,179

Title:	Death domain containing receptor 4 antibodies and methods
Abstract:	The present invention relates to novel Death Domain Containing Receptor-4 (DR4) proteins which are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR4 proteins. DR4 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of DR4 activity and methods for using DR4 polynucleotides and polypeptides. The invention also relates to the treatment of diseases associated with reduced or increased levels of apoptosis using antibodies specific for DR4, which may be agonists and/or antagonists of DR4 activity.
Inventor(s):	Ni; Jian (Germantown, MD), Rosen; Craig A. (Laytonsville, MD), Pan; James G. (Toronto, CA), Gentz; Reiner L. (Belo Horizonte-MG, BR), Dixit; Vishva M. (Los Altos Hills, CA)
Assignee:	Human Genome Sciences, Inc. (Rockville, MD) The Regents of the University of Michigan (Ann Arbor, MI)
Application Number:	12/010,108
Patent Claims:	1. A method for inducing apoptosis of a DR4-expressing cell, comprising contacting said cell with an agonist antibody or fragment thereof that specifically binds to a polypeptide consisting of amino acids 24 to 238 of SEQ ID NO:2 in combination with a second agent selected from the group consisting of: (a) an alkylating agent; (b) an antimetabolite; (c) a farnesyl transferase inhibitor; (d) a mitotic spindle inhibitor; (e) a topoisomerase inhibitor; (f) a tyrosine kinase inhibitor; (g) a proteasome inhibitor; (h) an antibiotic; (i) a histone deacetylase inhibitor; (j) a HSP90 inhibitor; (k) thalidomide; (l) a thalidomide analog; (m) a monoclonal antibody; (n) radiation therapy; (o) a AKT/mTOR signaling pathway inhibitor; and (p) a BCL-2 inhibitor. 2. The method of claim 1, wherein said alkylating agent is a nitrogen mustard. 3. The method of claim 1, wherein said alkylating agent is carboplatin. 4. The method of claim 1, wherein said alkylating agent is cisplatin. 5. The method of claim 1, wherein said alkylating agent is oxaliplatin. 6. The method of claim 1, wherein said antimetabolite is methotrexate. 7. The method of claim 1, wherein said antimetabolite is fluorouracil+leucovorin. 8. The method of claim 1, wherein said antimetabolite is cytosine arabinoside. 9. The method of claim 1, wherein said antimetabolite is pemetrexed. 10. The method of claim 1, wherein said antimetabolite is gemcitabine. 11. The method of claim 1, wherein said antimetabolite is capecitabine. 12. The method of claim 1, wherein said mitotic spindle inhibitor is docetaxel. 13. The method of claim 1, wherein said mitotic spindle inhibitor is paclitaxel. 14. The method of claim 1, wherein said mitotic spindle inhibitor is vincristine. 15. The method of claim 1, wherein said mitotic spindle inhibitor is vinblastine. 16. The method of claim 1, wherein said topoisomerase inhibitor is 9-aminocamptothecin. 17. The method of claim 1, wherein said topoisomerase inhibitor is topotecan. 18. The method of claim 1, wherein said topoisomerase inhibitor is irinotecan. 19. The method of claim 1, wherein said topoisomerase inhibitor is etoposide. 20. The method of claim 1, wherein said tyrosine kinase inhibitor is imatinib mesylate. 21. The method of claim 1, wherein said tyrosine kinase inhibitor is BAY 43-9006. 22. The method of claim 1, wherein said proteasome inhibitor is PS-341. 23. The method of claim 1, wherein said proteasome inhibitor is NPI-0052. 24. The method of claim 1, wherein said antibiotic is bleomycin. 25. The method of claim 1, wherein said antibiotic is daunorubicin. 26. The method of claim 1, wherein said antibiotic is doxorubicin. 27. The method of claim 1, wherein said antibiotic is dactinomycin. 28. The method of claim 1, wherein said monoclonal antibody is bevacizumab. 29. The method of claim 1, wherein said monoclonal antibody is rituximab. 30. The method of claim 1, wherein said thalidomide analog is revlimid. 31. A method for treating cancer, comprising administering to a patient therapeutically effective amounts of an agonist antibody or fragment thereof that specifically binds to a polypeptide consisting of amino acids 24 to 238 of SEQ ID NO:2 in combination with a second agent selected from the group consisting of: (a) a tyrosine kinase inhibitor; (b) a proteasome inhibitor; (c) an antibiotic; (d) a histone deacetylase inhibitor; (e) a HSP90 inhibitor; (f) thalidomide; (g) a thalidomide analog; (h) a monoclonal antibody; (i) radiation therapy; (j) a AKT/mTOR signaling pathway inhibitor; and (k) a BCL-2 inhibitor. 32. The method of claim 31, wherein said tyrosine kinase inhibitor is BAY 43-9006. 33. The method of claim 31, wherein said proteasome inhibitor is NPI-0052. 34. The method of claim 31, wherein said antibiotic is bleomycin. 35. The method of claim 31, wherein said antibiotic is daunorubicin. 36. The method of claim 31, wherein said antibiotic is doxorubicin. 37. The method of claim 31, wherein said antibiotic is dactinomycin. 38. The method of claim 31, wherein said monoclonal antibody is bevacizumab. 39. The method of claim 31, wherein said monoclonal antibody is rituximab. 40. The method of claim 31, wherein said thalidomide analog is revlimid. 41. A method of treating cancer, comprising administering to a patient a therapeutically effective amount of an agonist antibody or fragment thereof that specifically binds to a polypeptide consisting of amino acids 24 to 238 of SEQ ID NO:2, wherein said cancer is selected from the group consisting of: (a) multiple myeloma; (b) bile duct cancer; (c) hepatoma; and (d) non-small cell lung cancer. 42. The method of claim 41, wherein said cancer is multiple myeloma. 43. The method of claim 41, wherein said cancer is bile duct cancer. 44. The method of claim 41, wherein said cancer is a hepatoma. 45. The method of claim 41, wherein said cancer is non-small cell lung cancer. 46. The method of claim 1, wherein said antibody or fragment thereof is a monoclonal antibody. 47. The method of claim 1, wherein said antibody or fragment thereof is selected from the group consisting of: (a) a polyclonal antibody; (b) a chimeric antibody; (c) a human antibody; (d) a humanized antibody; (e) a single-chain Fv antibody; and (f) an Fab antibody fragment. 48. The method of claim 1, wherein said antibody or fragment thereof is pegylated. 49. The method of claim 1, wherein said antibody or fragment thereof is fused to a heterologous polypeptide. 50. The method of claim 1, wherein said cell is contacted by said antibody or fragment thereof and said second agent simultaneously. 51. The method of claim 1, wherein said cell is contacted by said antibody or fragment thereof and said second agent sequentially. 52. The method of claim 1, which is in vitro. 53. The method of claim 1, which is in vivo. 54. The method of claim 1, wherein said cell is a cancer cell. 55. The method of claim 31, wherein said antibody or fragment thereof is a monoclonal antibody. 56. The method of claim 31, wherein said antibody or fragment thereof is selected from the group consisting of: (a) a polyclonal antibody; (b) a chimeric antibody; (c) a human antibody; (d) a humanized antibody; (e) a single-chain Fv antibody; and (f) an Fab antibody fragment. 57. The method of claim 31, wherein said antibody or fragment thereof is pegylated. 58. The method of claim 31, wherein said antibody or fragment thereof is fused to a heterologous polypeptide. 59. The method of claim 31, wherein said antibody or fragment thereof and said second agent are administered to the patient simultaneously. 60. The method of claim 31, wherein said antibody or fragment thereof and said second agent are administered to the patient sequentially. 61. The method of claim 41, wherein said antibody or fragment thereof is a monoclonal antibody. 62. The method of claim 41, wherein said antibody or fragment thereof is selected from the group consisting of: (a) a polyclonal antibody; (b) a chimeric antibody; (c) a human antibody; (d) a humanized antibody; (e) a single-chain Fv antibody; and (f) an Fab antibody fragment. 63. The method of claim 41, wherein said antibody or fragment thereof is pegylated. 64. The method of claim 41, wherein said antibody or fragment thereof is fused to a heterologous polypeptide.

Details for Patent 8,329,179

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2017-01-28
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2017-01-28
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2017-01-28
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017		2017-01-28